PT102548A - Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant) - Google Patents

Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant)

Info

Publication number: PT102548A
Authority: PT; Portugal
Prior art keywords: pentafluoropentilsulfinyl; 7alfa; 17beta; estra; trien
Prior art date: 2000-01-10

Application number

PT102548A

Other languages

English (en)

Inventor

John Raymond Evans

Rosalind Ursula Grundy

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-10

Filing date

2001-01-09

Publication date

2001-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT102548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-09 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-07-31 Publication of PT102548A publication Critical patent/PT102548A/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PT102548A 2000-01-10 2001-01-09 Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant) PT102548A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0000313.7A GB0000313D0 (en)	2000-01-10	2000-01-10	Formulation
GBGB0008837.7A GB0008837D0 (en)	2000-01-10	2000-04-12	Formulation

Publications (1)

Publication Number	Publication Date
PT102548A true PT102548A (pt)	2001-07-31

Family

ID=26243352

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT101806677T PT2266573E (pt)	2000-01-10	2001-01-08	Formulação de fulvestrant
PT102548A PT102548A (pt)	2000-01-10	2001-01-09	Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil\| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT101806677T PT2266573E (pt)	2000-01-10	2001-01-08	Formulação de fulvestrant

Country Status (41)

Country	Link
US (5)	US20030125387A1 (pt)
EP (4)	EP1669073A3 (pt)
JP (3)	JP3713237B2 (pt)
KR (1)	KR100802366B1 (pt)
CN (1)	CN1222292C (pt)
AR (1)	AR027510A1 (pt)
AT (1)	ATE306928T1 (pt)
AU (1)	AU762080B2 (pt)
BE (1)	BE1013477A3 (pt)
BG (1)	BG65776B1 (pt)
BR (1)	BR0107445B1 (pt)
CA (1)	CA2351004C (pt)
CH (1)	CH696260A5 (pt)
CO (1)	CO5280206A1 (pt)
CY (1)	CY1116520T1 (pt)
CZ (1)	CZ304689B6 (pt)
DE (2)	DE60114145T3 (pt)
DK (2)	DK2266573T3 (pt)
EE (1)	EE05421B1 (pt)
EG (1)	EG24074A (pt)
ES (3)	ES2543384T3 (pt)
FR (1)	FR2803516B1 (pt)
GB (3)	GB0000313D0 (pt)
HK (3)	HK1049286B (pt)
HU (1)	HU230162B1 (pt)
IL (2)	IL150230A0 (pt)
IS (1)	IS2932B (pt)
IT (2)	ITTO20010005A1 (pt)
MX (1)	MXPA02006698A (pt)
MY (1)	MY118583A (pt)
NL (1)	NL1017075C2 (pt)
NO (2)	NO336286B1 (pt)
PL (1)	PL202525B1 (pt)
PT (2)	PT2266573E (pt)
RU (1)	RU2263507C9 (pt)
SI (2)	SI2266573T1 (pt)
SK (1)	SK287221B6 (pt)
TW (1)	TWI259086B (pt)
UA (1)	UA75879C2 (pt)
WO (1)	WO2001051056A1 (pt)
ZA (1)	ZA200204165B (pt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
GB0116620D0 (en) *	2001-07-07	2001-08-29	Astrazeneca Ab	Formulation
CN1553815A (zh) *	2001-07-07	2004-12-08		用于肌内给药的氟维司群药物制剂
MXPA04011624A (es)	2002-05-24	2005-03-07	Schering Corp	Anticuerpo neutralizante humano anti-igfr.
TW200404552A (en) *	2002-05-30	2004-04-01	Akzo Nobel Nv	Self administered contraception
US20050152858A1 (en) *	2003-07-11	2005-07-14	Isp Investments Inc.	Solubilizing agents for active or functional organic compounds
PE20050928A1 (es) *	2003-11-21	2005-11-08	Schering Corp	Combinaciones terapeuticas de anticuerpo anti-igfr1
EP1623713A1 (en) *	2004-07-09	2006-02-08	Proskelia SAS	Cominations of pure anti-estrogen with aromatase inhibitors
AU2006236637B2 (en) *	2005-04-15	2012-09-06	Merck Sharp & Dohme Corp.	Methods and compositions for treating or preventing cancer
EP1928469A4 (en) *	2005-09-26	2008-12-31	Hospira Australia Pty Ltd	Fulvestrant FORMULATION
KR20100121505A (ko) *	2008-03-07	2010-11-17	싸이도우스 엘엘씨.	플배스트랜 제제
AU2014200332B2 (en) *	2008-04-28	2016-10-06	Diurnal Limited	Lipid composition
GB0807605D0 (en) *	2008-04-28	2008-06-04	Diurnal Ltd	Lipid composition
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en)	2009-06-16	2010-12-16	Endorecherche, Inc.	Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CA2800673A1 (en)	2010-06-10	2011-12-15	Aragon Pharmaceuticals, Inc.	Estrogen receptor modulators and uses thereof
WO2011159769A2 (en)	2010-06-17	2011-12-22	Aragon Pharmaceuticals, Inc.	Indane estrogen receptor modulators and uses thereof
EP2616078B1 (en)	2010-09-16	2019-12-25	Shimoda Biotech (Pty) Ltd	Fulvestrant compositions and methods of use
EP2711010B1 (en) *	2011-05-20	2018-10-31	Capital, Business Y Gestión De Finanzas, S.L	Pharmaceutical composition
CN102391341B (zh) *	2011-08-09	2013-05-22	福建省微生物研究所	制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) *	2011-10-26	2015-04-15	正大天晴药业集团股份有限公司	一种氟维司群的药物组合物
ES2885523T3 (es)	2011-11-23	2021-12-14	Therapeuticsmd Inc	Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
EP2791132A4 (en)	2011-12-14	2015-08-05	Seragon Pharmaceuticals Inc	ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
BR112014014767A2 (pt)	2011-12-16	2017-06-13	Olema Pharmaceuticals Inc	novos compostos de benzopirano, composições e usos dos mesmos
CN102600064A (zh) *	2012-03-31	2012-07-25	西安力邦制药有限公司	氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh) *	2012-03-31	2014-01-01	莱普德制药有限公司	以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US11179468B2 (en)	2012-04-09	2021-11-23	Eagle Pharmaceuticals, Inc.	Fulvestrant formulations
ES2983451T3 (es) *	2012-04-09	2024-10-23	Eagle Pharmaceuticals Inc	Formulaciones de Fulvestrant
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
AU2013386732B2 (en)	2013-04-18	2018-10-18	Xi'an Libang Pharmaceutical Technology Co., Ltd.	Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
US10392667B2 (en)	2013-06-07	2019-08-27	Medical Prognosis Institute A/S	Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203129A1 (en)	2013-06-19	2014-12-24	Olema Pharmaceuticals, Inc.	Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en)	2013-06-19	2014-12-24	Olema Pharmaceuticals, Inc.	Substituted benzopyran compounds, compositions and uses thereof
CN104337761B (zh) *	2013-08-07	2019-03-26	江苏豪森药业集团有限公司	氟维司群药物组合物
US20160213682A1 (en) *	2013-09-06	2016-07-28	Salah Uddin Ahmed	Fulvestrant compositions
US9271990B2 (en)	2014-02-14	2016-03-01	Fresenius Kabi Usa, Llc	Fulvestrant formulations
US20150258080A1 (en)	2014-03-13	2015-09-17	Genentech, Inc.	Therapeutic combinations with estrogen receptor modulators
KR20170005819A (ko)	2014-05-22	2017-01-16	쎄러퓨틱스엠디, 인코퍼레이티드	천연 복합 호르몬 대체 제형 및 요법
CA2951284A1 (en)	2014-07-29	2016-02-04	Therapeuticsmd, Inc.	Transdermal cream
EA032311B1 (ru)	2014-12-18	2019-05-31	Ф. Хоффманн-Ля Рош Аг	Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
KR102710603B1 (ko)	2015-10-01	2024-09-27	올레마 파마슈티컬스 인코포레이티드	테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
JP2018530597A (ja)	2015-10-13	2018-10-18	テミスメディケアリミティド	フルベストラント組成物
PL3386500T3 (pl)	2015-12-09	2023-03-13	The Board Of Trustees Of The University Of Illinois	Selektywne antagonisty receptora estrogenowego na bazie benzotiofenu
JP2019513709A (ja)	2016-04-01	2019-05-30	セラピューティックスエムディーインコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ，Ｉｎｃ．	ステロイドホルモン薬学的組成物
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
JP6682163B2 (ja) *	2016-04-06	2020-04-15	富士フイルム株式会社	医薬組成物
US9969732B2 (en)	2016-04-08	2018-05-15	Genentech, Inc.	Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
JP2019516789A (ja) *	2016-05-06	2019-06-20	イーグルファーマスーティカルズ、インク．	フルベストラント配合物およびその使用方法
US11590077B2 (en)	2016-05-06	2023-02-28	Eagle Pharmaceuticals, Inc.	Fulvestrant formulations and methods of their use
CN109152785B (zh) *	2016-05-31	2021-02-09	富士胶片株式会社	医药组合物
JP7018026B2 (ja) *	2016-06-16	2022-02-09	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	ヘテロアリールエストロゲン受容体モジュレーター及びその使用
US20180002344A1 (en)	2016-06-16	2018-01-04	Genentech, Inc.	Heteroaryl estrogen receptor modulators and uses thereof
WO2017216280A1 (en)	2016-06-16	2017-12-21	F. Hoffmann-La Roche Ag	TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN107789320B (zh) *	2016-08-31	2021-06-22	鲁南制药集团股份有限公司	一种氟维司群缓释注射液及其制备工艺
KR20240155974A (ko)	2017-09-11	2024-10-29	아토사 테라퓨틱스, 인크.	엔독시펜을 제조 및 사용하는 방법
JP7220712B2 (ja) *	2017-11-08	2023-02-10	イーグルファーマスーティカルズ、インク．	フルベストラント製剤とその使用方法
US20200277378A1 (en)	2017-11-16	2020-09-03	Novartis Ag	Combination therapies
CN111465398A (zh) *	2018-01-31	2020-07-28	富士胶片株式会社	注射用制剂的制造方法
RU2684330C1 (ru) *	2018-02-02	2019-04-08	Закрытое Акционерное Общество "Биокад"	Композиции фулвестранта
WO2019224790A2 (en)	2018-05-24	2019-11-28	Kashiv Biosciences, Llc	Prodrugs of fulvestrant
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) *	2018-10-12	2020-04-21	江苏恒瑞医药股份有限公司	一种包含氟维司群的可注射的药物组合物及其制备方法
US20210401859A1 (en)	2018-11-01	2021-12-30	Syros Pharmaceuticals, Inc.	Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
CN113271945A (zh)	2018-12-20	2021-08-17	诺华股份有限公司	包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
CN113329792B (zh)	2019-02-15	2024-06-28	诺华股份有限公司	取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20220144807A1 (en)	2019-02-15	2022-05-12	Novartis Ag	3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021023229A2 (pt)	2019-05-20	2022-05-31	Servier Lab	Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso
RU2722988C1 (ru) *	2019-11-19	2020-06-05	федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
US20220370359A1 (en) *	2019-12-11	2022-11-24	Shanghai Bocimed Pharmaceutical Co., Ltd.	Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof
CN115175937A (zh)	2019-12-20	2022-10-11	诺华股份有限公司	用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
KR20230027056A (ko)	2020-06-23	2023-02-27	노파르티스 아게	3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP2023536164A (ja)	2020-08-03	2023-08-23	ノバルティスアーゲー	ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
MX2023006010A (es)	2020-11-24	2023-06-08	Novartis Ag	Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos.
EP4251208A1 (en)	2020-11-24	2023-10-04	Novartis AG	Mcl-1 inhibitor antibody-drug conjugates and methods of use
CA3206906A1 (en)	2021-02-02	2022-08-11	Andras Herner	Selective bcl-xl protac compounds and methods of use
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
WO2023121232A1 (ko) *	2021-12-20	2023-06-29	주식회사 삼양홀딩스	용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
AR129382A1 (es)	2022-05-20	2024-08-21	Novartis Ag	Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso
WO2023225320A1 (en)	2022-05-20	2023-11-23	Novartis Ag	Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2024189481A1 (en)	2023-03-10	2024-09-19	Novartis Ag	Panras inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB817241A (en)	1957-08-21	1959-07-29	Vismara Francesco Spa	Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr)	1905-04-19	1906-10-10	Ktiengesellschaft	Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de)	1954-10-19	1956-08-16	Schering Ag	Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en)	1957-10-15	1961-05-09	Francesco Vismara Societa Per	Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) *	1962-09-11	1967-03-08	Olin Mathieson	Steroid compositions
US3164520A (en) †	1962-10-29	1965-01-05	Olin Mathieson	Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (pt)	1965-01-07	1968-11-12
NL151903B (nl)	1965-03-24	1977-01-17	Schering Ag	Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) *	1965-05-05	1976-01-20	Schering Aktiengesellschaft	17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) *	1967-01-13	1970-10-07	Takeda Chemical Industries Ltd	Injectable composition
SU549118A1 (ru)	1973-04-02	1977-03-05		Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru)	1975-06-26	1979-07-30	Научно-Исследовательский Институт Животноводства	Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de)	1975-10-27	1977-04-28	Schering Ag	Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048310A (en)	1976-02-24	1977-09-13	E. R. Squibb & Sons, Inc.	Topical steroid formulation in form of lotion or cream
US4048309A (en)	1976-02-24	1977-09-13	E. R. Squibb & Sons, Inc.	Topical steroid ointment formulations
NL7711916A (nl)	1977-10-29	1979-05-02	Akzo Nv	Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
SE445174B (sv) *	1978-03-07	1986-06-09	Sandoz Ag	Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
GB8327256D0 (en)	1983-10-12	1983-11-16	Ici Plc	Steroid derivatives
DE3708942A1 (de)	1987-03-18	1988-09-29	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (de) *	1987-10-01	1994-06-08	Schering Aktiengesellschaft	Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de)	1987-10-01	1989-04-13	Schering Ag	Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en)	1988-06-06	1988-07-13	Ici Plc	Therapeutic product
JPH04327327A (ja)	1991-04-25	1992-11-16	Toyoda Gosei Co Ltd	スリーブとホースの加締め用ダイス
CN1102095A (zh)	1993-10-30	1995-05-03	浙江医科大学	长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en)	1994-01-28	2000-07-26	Abbott Lab	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) *	1994-12-23	1996-07-03	Schering Ag	Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
DE19510861A1 (de)	1995-03-16	1996-09-19	Schering Ag	Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
US20010006963A1 (en)	1995-03-16	2001-07-05	Ursula Lachnit-Fixson	Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
EP0760237A1 (en)	1995-08-30	1997-03-05	Cipla Limited	Oil-in-water microemulsions
GB9525194D0 (en) *	1995-12-12	1996-02-07	Zeneca Ltd	Pharmaceutical composition
JPH09208496A (ja) *	1996-01-30	1997-08-12	Takeda Chem Ind Ltd	Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de)	1996-04-09	1997-10-16	Bayer Ag	Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en)	1996-04-26	1996-07-03	Scherer Ltd R P	Pharmaceutical compositions
US5952338A (en)	1996-07-05	1999-09-14	Takeda Chemical Industries, Ltd.	Agent for prophylaxis and treatment of disturbance of visual function
JPH10203982A (ja) *	1996-07-05	1998-08-04	Takeda Chem Ind Ltd	視機能障害の予防・治療剤
DE19635525A1 (de) *	1996-08-20	1998-02-26	Schering Ag	7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de)	1996-09-18	1998-03-19	Bayer Ag	Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) *	1996-11-22	1998-06-09	Takeda Chem Ind Ltd	１−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
JPH11158200A (ja) *	1997-09-26	1999-06-15	Takeda Chem Ind Ltd	ヒト成長ホルモン・亜鉛複合体及びその用途
US6191107B1 (en)	1997-09-26	2001-02-20	Takeda Chemical Industries, Ltd.	Complex of human growth hormone and zinc
NZ504783A (en)	1997-12-03	2002-12-20	Merck & Co Inc	Long acting injectable formulations containing hydrogenated castor oil
EP2266537B1 (en)	1999-04-01	2014-09-03	Hana Biosciences, Inc.	Compositions for treating cancer
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
JP4327327B2 (ja)	2000-04-03	2009-09-09	ロボテック株式会社	固定スプレー揺動装置
CN1553815A (zh)	2001-07-07	2004-12-08		用于肌内给药的氟维司群药物制剂
GB0912999D0 (en)	2009-07-27	2009-09-02	Astrazeneca Ab	Method-803

2000
- 2000-01-10 GB GBGB0000313.7A patent/GB0000313D0/en not_active Ceased
- 2000-04-12 GB GBGB0008837.7A patent/GB0008837D0/en not_active Ceased
2001
- 2001-01-08 RU RU2002121507A patent/RU2263507C9/ru active
- 2001-01-08 KR KR1020027008855A patent/KR100802366B1/ko active IP Right Grant
- 2001-01-08 WO PCT/GB2001/000049 patent/WO2001051056A1/en active IP Right Grant
- 2001-01-08 DK DK10180667.7T patent/DK2266573T3/en active
- 2001-01-08 EP EP05016921A patent/EP1669073A3/en not_active Withdrawn
- 2001-01-08 PT PT101806677T patent/PT2266573E/pt unknown
- 2001-01-08 ES ES10180667.7T patent/ES2543384T3/es not_active Expired - Lifetime
- 2001-01-08 CN CNB018035469A patent/CN1222292C/zh not_active Ceased
- 2001-01-08 GB GB0100407A patent/GB2359254B/en not_active Expired - Lifetime
- 2001-01-08 SI SI200131044T patent/SI2266573T1/sl unknown
- 2001-01-08 AU AU23863/01A patent/AU762080B2/en not_active Expired
- 2001-01-08 SK SK984-2002A patent/SK287221B6/sk not_active IP Right Cessation
- 2001-01-08 EG EG20010017A patent/EG24074A/xx active
- 2001-01-08 JP JP2001551480A patent/JP3713237B2/ja not_active Expired - Lifetime
- 2001-01-08 EP EP01900186.6A patent/EP1250138B2/en not_active Expired - Lifetime
- 2001-01-08 IL IL15023001A patent/IL150230A0/xx active IP Right Grant
- 2001-01-08 US US10/169,777 patent/US20030125387A1/en not_active Abandoned
- 2001-01-08 MX MXPA02006698A patent/MXPA02006698A/es active IP Right Grant
- 2001-01-08 EP EP10180667.7A patent/EP2266573B1/en not_active Expired - Lifetime
- 2001-01-08 ES ES01900186.6T patent/ES2248272T5/es not_active Expired - Lifetime
- 2001-01-08 PL PL356030A patent/PL202525B1/pl unknown
- 2001-01-08 SI SI200130446T patent/SI1250138T2/sl unknown
- 2001-01-08 CZ CZ2002-2384A patent/CZ304689B6/cs not_active IP Right Cessation
- 2001-01-08 DK DK01900186.6T patent/DK1250138T4/en active
- 2001-01-08 BR BRPI0107445-8A patent/BR0107445B1/pt active IP Right Grant
- 2001-01-08 AT AT01900186T patent/ATE306928T1/de active
- 2001-01-08 HU HU0204137A patent/HU230162B1/hu not_active IP Right Cessation
- 2001-01-08 CA CA002351004A patent/CA2351004C/en not_active Expired - Fee Related
- 2001-01-08 DE DE60114145.8T patent/DE60114145T3/de not_active Expired - Lifetime
- 2001-01-08 EP EP10180661.0A patent/EP2286818B1/en not_active Expired - Lifetime
- 2001-01-08 EE EEP200200387A patent/EE05421B1/xx unknown
- 2001-01-09 IT IT000005A patent/ITTO20010005A1/it unknown
- 2001-01-09 US US09/756,291 patent/US6774122B2/en not_active Expired - Lifetime
- 2001-01-09 BE BE2001/0021A patent/BE1013477A3/fr not_active IP Right Cessation
- 2001-01-09 PT PT102548A patent/PT102548A/pt not_active Application Discontinuation
- 2001-01-10 IT IT2001TO000008A patent/ITTO20010008A1/it unknown
- 2001-01-10 ES ES200100057A patent/ES2186517B2/es not_active Expired - Fee Related
- 2001-01-10 CO CO01001317A patent/CO5280206A1/es not_active Application Discontinuation
- 2001-01-10 NL NL1017075A patent/NL1017075C2/nl not_active IP Right Cessation
- 2001-01-10 CH CH00029/01A patent/CH696260A5/de not_active IP Right Cessation
- 2001-01-10 AR ARP010100100A patent/AR027510A1/es not_active Application Discontinuation
- 2001-01-10 DE DE10100779A patent/DE10100779A1/de not_active Ceased
- 2001-01-10 MY MYPI20010107A patent/MY118583A/en unknown
- 2001-01-10 FR FR0100248A patent/FR2803516B1/fr not_active Expired - Lifetime
- 2001-01-10 TW TW090100514A patent/TWI259086B/zh active
- 2001-08-01 UA UA2002086628A patent/UA75879C2/uk unknown
2002
- 2002-05-24 ZA ZA200204165A patent/ZA200204165B/xx unknown
- 2002-06-13 IL IL150230A patent/IL150230A/en unknown
- 2002-06-18 BG BG106833A patent/BG65776B1/bg unknown
- 2002-07-03 NO NO20023227A patent/NO336286B1/no not_active IP Right Cessation
- 2002-07-03 IS IS6454A patent/IS2932B/is unknown
2003
- 2003-02-28 HK HK03101532.0A patent/HK1049286B/zh not_active IP Right Cessation
- 2003-07-21 HK HK03105241.3A patent/HK1052884B/zh not_active IP Right Cessation
- 2003-10-23 JP JP2003362875A patent/JP2004107353A/ja not_active Ceased
2004
- 2004-06-22 US US10/872,784 patent/US7456160B2/en not_active Expired - Lifetime
2008
- 2008-10-15 US US12/285,887 patent/US8329680B2/en active Active
2011
- 2011-04-18 HK HK11103860.8A patent/HK1150021A1/xx not_active IP Right Cessation
- 2011-06-20 JP JP2011135962A patent/JP2011190275A/ja active Pending
2012
- 2012-09-04 US US13/602,667 patent/US8466139B2/en not_active Expired - Lifetime
2015
- 2015-06-08 NO NO20150741A patent/NO337329B1/no not_active IP Right Cessation
- 2015-07-22 CY CY20151100648T patent/CY1116520T1/el unknown

Also Published As

Publication number	Publication date
PL202525B1 (pl)	2009-07-31
CA2351004C (en)	2003-02-18
ATE306928T1 (de)	2005-11-15
GB0100407D0 (en)	2001-02-21
US20030125387A1 (en)	2003-07-03
DE60114145T2 (de)	2006-07-13
ZA200204165B (en)	2003-10-29
CY1116520T1 (el)	2017-03-15
TWI259086B (en)	2006-08-01
BG65776B1 (bg)	2009-11-30
HK1052884B (zh)	2006-07-14
FR2803516A1 (fr)	2001-07-13
JP2003519659A (ja)	2003-06-24
NL1017075A1 (nl)	2001-07-11
HUP0204137A3 (en)	2005-03-29
SK9842002A3 (en)	2003-05-02
UA75879C2 (en)	2006-06-15
BG106833A (en)	2003-03-31
GB2359254B (en)	2002-06-19
KR100802366B1 (ko)	2008-02-13
EP1250138B2 (en)	2015-07-08
US20050043285A1 (en)	2005-02-24
EG24074A (en)	2008-05-11
AU2386301A (en)	2001-07-24
EP2266573A1 (en)	2010-12-29
DK2266573T3 (en)	2015-07-20
US20100152149A1 (en)	2010-06-17
SK287221B6 (sk)	2010-03-08
EP2286818B1 (en)	2020-03-18
EP2286818A1 (en)	2011-02-23
NO20150741L (no)	2002-07-03
GB2359254A (en)	2001-08-22
CN1222292C (zh)	2005-10-12
CZ304689B6 (cs)	2014-09-03
US8329680B2 (en)	2012-12-11
EE200200387A (et)	2003-10-15
JP3713237B2 (ja)	2005-11-09
IL150230A0 (en)	2002-12-01
EE05421B1 (et)	2011-06-15
ITTO20010005A0 (it)	2001-01-09
ITTO20010008A0 (it)	2001-01-10
ES2186517A1 (es)	2003-05-01
PL356030A1 (en)	2004-06-14
MXPA02006698A (es)	2002-09-30
US7456160B2 (en)	2008-11-25
RU2263507C2 (ru)	2005-11-10
EP1250138B1 (en)	2005-10-19
ES2543384T3 (es)	2015-08-18
EP1250138A1 (en)	2002-10-23
CZ20022384A3 (cs)	2002-09-11
DE60114145T3 (de)	2015-09-17
ES2186517B2 (es)	2004-03-16
GB0008837D0 (en)	2000-05-31
US20010020016A1 (en)	2001-09-06
JP2011190275A (ja)	2011-09-29
ITTO20010005A1 (it)	2001-07-11
CA2351004A1 (en)	2001-07-10
ES2248272T3 (es)	2006-03-16
BR0107445B1 (pt)	2012-10-30
MY118583A (en)	2004-12-31
SI2266573T1 (sl)	2015-08-31
AR027510A1 (es)	2003-04-02
FR2803516B1 (fr)	2003-03-28
WO2001051056A1 (en)	2001-07-19
DK1250138T4 (en)	2015-07-27
EP1669073A3 (en)	2008-03-19
HK1049286A1 (en)	2003-05-09
HU230162B1 (hu)	2015-09-28
ES2248272T5 (es)	2015-08-19
DE10100779A1 (de)	2001-07-26
GB0000313D0 (en)	2000-03-01
ITTO20010008A1 (it)	2002-07-10
NL1017075C2 (nl)	2001-09-25
JP2004107353A (ja)	2004-04-08
HK1052884A1 (en)	2003-10-03
HUP0204137A2 (hu)	2003-04-28
KR20020073499A (ko)	2002-09-26
AU762080B2 (en)	2003-06-19
IS2932B (is)	2015-12-15
BR0107445A (pt)	2002-09-17
IS6454A (is)	2002-07-03
DK1250138T3 (da)	2006-01-23
DE60114145D1 (de)	2006-03-02
NO337329B1 (no)	2016-03-14
PT2266573E (pt)	2015-07-28
CO5280206A1 (es)	2003-05-30
EP2266573B1 (en)	2015-06-17
HK1150021A1 (en)	2011-10-28
SI1250138T2 (sl)	2015-09-30
SI1250138T1 (sl)	2006-02-28
US6774122B2 (en)	2004-08-10
NO20023227D0 (no)	2002-07-03
CH696260A5 (de)	2007-03-15
BE1013477A3 (fr)	2002-02-05
CN1394141A (zh)	2003-01-29
IL150230A (en)	2006-10-31
US20120329766A1 (en)	2012-12-27
RU2263507C9 (ru)	2020-07-28
US8466139B2 (en)	2013-06-18
RU2002121507A (ru)	2004-03-20
NO20023227L (no)	2002-07-03
HK1049286B (zh)	2006-04-07
EP1669073A2 (en)	2006-06-14
NO336286B1 (no)	2015-07-13

Publication	Publication Date	Title
PT102548A (pt)	2001-07-31	Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil\| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant)
DK1283700T3 (da)	2006-07-24	Farmaceutiske sustained release-præparater til parenteral administration af biologisk aktive hydrofile forbindelser
UY27552A1 (es)	2003-06-30	17a- alquil- 17b- oxi-estratrienos y productos intermediarios para su preparacinn, uso de los 17a-alquil-17b-oxi-estratrienos para obtener medicamentos y preparados farmacéuticos.
NO20011721D0 (no)	2001-04-05	N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
NO20032510L (no)	2003-06-03	Organiske forbindelser
BR9910583A (pt)	2001-01-09	Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
EE05123B1 (et)	2009-02-16	Antiprogestiinsete omadustega ravimite manustamise vahendid
NO20042811L (no)	2004-07-05	Substituerte henzoksazoler og analoger som estrogene midler
HUP0400070A2 (hu)	2004-04-28	17alfa-helyzetben ciklusos észtercsoportot tartalmazó androsztán-17béta-karbotiosav-észter-származékok mint gyulladásgátló szerek, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények
BRPI0215312B8 (pt)	2021-05-25	composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
CY1107142T1 (el)	2012-10-24	Τυποποιηση που περιλαμβανει fulvestrant
WO1999055332A8 (fr)	2000-02-17	Compositions medicinales
TR200103395T2 (tr)	2002-04-22	13-metil eritromisin türevleri.
DE602004011966D1 (en)	2008-04-03	Heterocyclylverbindungen
MY129450A (en)	2007-04-30	Pharmaceutical composition
BR0113590A (pt)	2003-07-22	7-oxo-piridopirimidinas
AR034223A1 (es)	2004-02-04	Novedosa indicacion terapeutica de azitromicina para el tratamiento de enfermedades inflamatorias no infecciosas
HUP0400115A3 (en)	2005-11-28	Pharmaceutical composition for the intramuscular administration of fulvestrant
FI20000780A (fi)	2001-10-04	Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
ATE348599T1 (de)	2007-01-15	Pharmazeutische dronedaron-zusammensetzung für die parenterale verabreichung
BR0009476A (pt)	2002-02-19	Esteróides imunomoduladores, em particular hemidrato de 16 alfa-bromoepiandrosterona
NO20010219L (no)	2001-03-15	Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel
UY26530A1 (es)	2001-07-31	Composición.
DK1652526T3 (da)	2009-05-18	Anvendelse af (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-on i behandling af svær depressionslidelse
FR2861992B1 (fr)	2007-07-20	Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.

Legal Events

Date	Code	Title	Description
2001-07-31	BB1A	Laying open of patent application	Effective date: 20010319
2003-08-29	BB1A	Laying open of patent application	Effective date: 20030618
2016-02-16	FC3A	Refusal	Effective date: 20160211